Auditors Resign at Astal Labs Unit, Sparking Audit Delay Concerns

Auditors of Astal Laboratories' material subsidiary, Sriven Pharmachem India Private Limited, have resigned effective May 13, 2026. The resignation prevents the auditors from signing the audit reports for the financial year ending March 31, 2026.

The Announcement

Astal Laboratories Ltd informed the stock exchanges that the statutory auditors of its material subsidiary, Sriven Pharmachem India Private Limited, have resigned. The auditors, M/s. Balaji V & Co., cited the pending requirement of a Peer Review Certificate as the reason for their resignation. This resignation becomes effective from May 13, 2026. Crucially, this prevents the auditors from signing the audit reports for the financial period ending March 31, 2026.

The Impact

The resignation requires Astal Laboratories to quickly appoint new statutory auditors for Sriven Pharmachem India Private Limited. This situation could significantly delay the completion of the subsidiary's audit for the fiscal year ended March 31, 2026. Delays in finalizing the subsidiary's, and therefore the consolidated, financial statements could raise compliance issues.

Company Background

Astal Laboratories is engaged in the manufacturing of Active Pharmaceutical Ingredients (APIs), intermediates, and specialty chemicals. Sriven Pharmachem India Private Limited operates as a material subsidiary, indicating its significant contribution to Astal's overall business. Auditors are required by regulatory bodies to possess certain certifications, such as a Peer Review Certificate, to ensure audit quality and compliance.

What Happens Now

• Astal Laboratories must urgently identify and appoint new statutory auditors for Sriven Pharmachem India Private Limited.
• The timeline for completing the FY26 audit for the subsidiary is now uncertain.
• Investors will be watching for how quickly the company can secure new auditors to mitigate reporting delays.
• The finalization of consolidated financial results for FY26 might be postponed.

Key Risks

• Execution Risk: Delays in appointing new auditors could further postpone the completion of the FY26 audit.
• Financial Risk: An inability to secure timely audit reports might affect the finalization of financial statements and disclosures, potentially leading to regulatory scrutiny.

Peer Landscape

Astal Laboratories operates in the pharmaceutical API and intermediates sector, alongside peers like Divi's Laboratories, Laurus Labs, and Granules India. However, specific peer data on auditor stability or compliance issues related to peer review certificates is not readily available for direct comparison in this context.

What to Watch

• The speed and efficiency of appointing new statutory auditors for Sriven Pharmachem India Private Limited.
• Confirmation of the new auditor's acceptance and their projected timeline for completing the FY26 audit.
• Any further updates from Astal Laboratories regarding the status of regulatory filings.
• The company's proactive measures to ensure compliance and transparency.